Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope.

Hamorsky KT, Kouokam JC, Dent MW, Grooms TN, Husk AS, Hume SD, Rogers KA, Villinger F, Morris MK, Hanson CV, Matoba N.

Mol Ther. 2019 Aug 9. pii: S1525-0016(19)30360-0. doi: 10.1016/j.ymthe.2019.07.021. [Epub ahead of print]

PMID:
31471224
2.

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.

Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, Blazkova J, Clarridge KE, Su HW, Lin CY, Tseng FC, Lai A, Yang FH, Lin CH, Tseng W, Lin HY, Finstad CL, Wong-Staal F, Hanson CV, Chun TW, Liao MJ.

N Engl J Med. 2019 Apr 18;380(16):1535-1545. doi: 10.1056/NEJMoa1802264.

PMID:
30995373
3.

A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.

Eggink LL, Spyroulias GA, Jones NG, Hanson CV, Hoober JK.

PLoS One. 2015 Jun 25;10(6):e0130532. doi: 10.1371/journal.pone.0130532. eCollection 2015.

4.

Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Planque SA, Mitsuda Y, Chitsazzadeh V, Gorantla S, Poluektova L, Nishiyama Y, Ochsenbauer C, Morris MK, Sapparapu G, Hanson CV, Massey RJ, Paul S.

AIDS. 2014 Sep 24;28(15):2201-11. doi: 10.1097/QAD.0000000000000392.

5.

Reducing infectivity of HIV upon exposure to surfaces coated with N,N-dodecyl, methyl-polyethylenimine.

Gerrard SE, Larson AM, Klibanov AM, Slater NK, Hanson CV, Abrams BF, Morris MK.

Biotechnol Bioeng. 2013 Jul;110(7):2058-62. doi: 10.1002/bit.24867. Epub 2013 Apr 7.

PMID:
23436242
6.

CD4 binding determinant mimicry for HIV vaccine design.

Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S.

Front Immunol. 2012 Dec 17;3:383. doi: 10.3389/fimmu.2012.00383. eCollection 2012.

7.

Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, Paul S.

J Immunol. 2012 Dec 1;189(11):5367-81. doi: 10.4049/jimmunol.1200981. Epub 2012 Oct 22.

8.

Nature and nurture of catalytic antibodies.

Paul S, Planque SA, Nishiyama Y, Hanson CV, Massey RJ.

Adv Exp Med Biol. 2012;750:56-75. doi: 10.1007/978-1-4614-3461-0_5.

PMID:
22903666
9.

A nipple shield delivery system for oral drug delivery to breastfeeding infants: microbicide delivery to inactivate HIV.

Gerrard SE, Baniecki ML, Sokal DC, Morris MK, Urdaneta-Hartmann S, Krebs FC, Wigdahl B, Abrams BF, Hanson CV, Slater NK, Edwards AD.

Int J Pharm. 2012 Sep 15;434(1-2):224-34. doi: 10.1016/j.ijpharm.2012.05.035. Epub 2012 May 24.

PMID:
22634141
10.

Vaccinogenicity.

Hanson CV.

AIDS. 2011 Mar 13;25(5):581-4. doi: 10.1097/QAD.0b013e3283440412. No abstract available.

PMID:
21252631
11.

HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Matoba N, Husk AS, Barnett BW, Pickel MM, Arntzen CJ, Montefiori DC, Takahashi A, Tanno K, Omura S, Cao H, Mooney JP, Hanson CV, Tanaka H.

PLoS One. 2010 Jun 15;5(6):e11143. doi: 10.1371/journal.pone.0011143.

12.

Inactivation of cell-associated and cell-free HIV-1 by flash-heat treatment of breast milk.

Volk ML, Hanson CV, Israel-Ballard K, Chantry CJ.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):665-6. doi: 10.1097/QAI.0b013e3181ba47df. No abstract available.

PMID:
20335743
13.

High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile Virus and St. Louis encephalitis virus.

Taketa-Graham M, Powell Pereira JL, Baylis E, Cossen C, Oceguera L, Patiris P, Chiles R, Hanson CV, Forghani B.

Am J Trop Med Hyg. 2010 Mar;82(3):501-4. doi: 10.4269/ajtmh.2010.09-0297. Erratum in: Am J Trop Med Hyg. 2010 Dec;83(6):1356. Forghani, BagHer [corrected to Forghani, Bagher].

14.

Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.

Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, Morris MK, Nishiyama Y, Ghosh D, Kumar A, Gao F, Hanson CV, Paul S.

AIDS. 2010 Mar 27;24(6):875-84. doi: 10.1097/QAD.0b013e3283376e88. Erratum in: AIDS. 2011 Jun 19;25(10):1345-6.

15.

Peptide sugar mimetics prevent HIV type 1 replication in peripheral blood mononuclear cells in the presence of HIV-positive antiserum.

Eggink LL, Salas M, Hanson CV, Hoober JK.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):149-60. doi: 10.1089/aid.2009.0155.

PMID:
20156098
16.

Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, Symersky J, Boivin S, Sienczyk M, Salas M, Hanson CV, Paul S.

J Biol Chem. 2009 Oct 30;284(44):30627-42. doi: 10.1074/jbc.M109.032185. Epub 2009 Sep 2.

17.

Over the falls? Rapid evolution of ecotypic differentiation in steelhead/rainbow trout (Oncorhynchus mykiss).

Pearse DE, Hayes SA, Bond MH, Hanson CV, Anderson EC, Macfarlane RB, Garza JC.

J Hered. 2009 Sep-Oct;100(5):515-25. doi: 10.1093/jhered/esp040. Epub 2009 Jun 26.

PMID:
19561050
18.

Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response.

Kittinunvorakoon C, Morris MK, Neeyapun K, Jetsawang B, Buehring GC, Hanson CV.

J Med Virol. 2009 May;81(5):768-78. doi: 10.1002/jmv.21465.

PMID:
19319941
19.

A covalent HIV vaccine: is there hope for the future?

Paul S, Planque SA, Nishiyama Y, Hanson CV.

Future Virol. 2009;4(1):7-10. No abstract available.

20.

Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, Hanson CV, Bomsel M, Mor TS.

Curr HIV Res. 2008 May;6(3):218-29.

21.

Serologic diagnosis of West Nile and St. Louis encephalitis virus infections in domestic chickens.

Patiris PJ, Oceguera LF 3rd, Peck GW, Chiles RE, Reisen WK, Hanson CV.

Am J Trop Med Hyg. 2008 Mar;78(3):434-41.

PMID:
18337340
22.

Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog.

Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson CV, Paul S.

J Biol Chem. 2007 Oct 26;282(43):31250-6. Epub 2007 Aug 29.

23.

Flavivirus serology by Western blot analysis.

Oceguera LF 3rd, Patiris PJ, Chiles RE, Busch MP, Tobler LH, Hanson CV.

Am J Trop Med Hyg. 2007 Jul;77(1):159-63.

PMID:
17620648
24.

Catalytic antibodies and their applications.

Hanson CV, Nishiyama Y, Paul S.

Curr Opin Biotechnol. 2005 Dec;16(6):631-6. Epub 2005 Oct 21. Review.

PMID:
16243512
25.

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.

Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L.

Transfusion. 2005 Apr;45(4):580-90.

PMID:
15819680
26.

Broadly distributed nucleophilic reactivity of proteins coordinated with specific ligand binding activity.

Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Hara M, Karle S, Hanson CV, Uda T, Paul S.

J Mol Recognit. 2005 Jul-Aug;18(4):295-306.

PMID:
15706608
27.

Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library.

Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, Lake D, Thiagarajan P, Arnett F, Hanson CV, Paul S.

AIDS. 2004 Jan 23;18(2):329-31.

PMID:
15075554
29.

Synthetic AIDS vaccine by targeting HIV receptor.

Wang CY, Shen M, Tam G, Fang XD, Ye J, Shen F, Walfield AM, Wang JJ, Li ML, Li XM, Salas M, Shearer MH, Kennedy RC, Hanson CV.

Vaccine. 2002 Nov 22;21(1-2):89-97.

PMID:
12443666
30.

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, DeVico A, Pal R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7. Epub 2002 Aug 21.

31.

Maternal HIV-1 antibody and vertical transmission in subtype C virus infection.

Guevara H, Casseb J, Zijenah LS, Mbizvo M, Oceguera LF 3rd, Hanson CV, Katzenstein DA, Hendry RM.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):435-40.

PMID:
11981358
32.

Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).

Morris MK, Katzenstein DA, Israelski D, Zolopa A, Hendry RM, Hanson CV.

J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):405-15.

PMID:
11744827
33.

Psoralen photochemical inactivation of Orientia tsutsugamushi in platelet concentrates.

Belanger KJ, Kelly DJ, Mettille FC, Hanson CV, Lippert LE.

Transfusion. 2000 Dec;40(12):1503-7.

PMID:
11134571
34.

HIV viral load and viral cultures in sexually active heterosexual men.

Buchacz K, Pan CY, van der Straten A, Hanson CV, Padian N.

J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):98-9. No abstract available.

PMID:
10708063
35.

Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.

Wang CY, Sawyer LS, Murthy KK, Fang X, Walfield AM, Ye J, Wang JJ, Chen PD, Li ML, Salas MT, Shen M, Gauduin MC, Boyle RW, Koup RA, Montefiori DC, Mascola JR, Koff WC, Hanson CV.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10367-72.

36.

Distribution of HIV type 1 (HIV-1) in blood components: detection and significance of high levels of HIV-1 associated with platelets.

Lee TH, Stromberg RR, Heitman JW, Sawyer L, Hanson CV, Busch MP.

Transfusion. 1998 Jun;38(6):580-8.

PMID:
9661692
37.

International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.

Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Jun;15(2):105-13.

PMID:
9346275
38.

Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.

Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L.

Transfusion. 1997 Apr;37(4):423-35.

PMID:
9111281
39.

International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.

Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Mar;15(1):41-8.

PMID:
9251847
40.

Human immunodeficiency virus in plasma and genital secretions during the menstrual cycle.

Goulston C, Stevens E, Gallo D, Mullins JI, Hanson CV, Katzenstein D.

J Infect Dis. 1996 Oct;174(4):858-61.

PMID:
8843230
41.

Immunoreactivity of Brazilian HIV isolates with different V3 motifs.

Hendry RM, Hanson CV, Bongertz V, Morgado M, Duarte A, Casseb J, Brigido L, Sabino E, Diaz R, Galv√£o-Castro B.

Mem Inst Oswaldo Cruz. 1996 May-Jun;91(3):347-8. No abstract available.

42.

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE.

J Infect Dis. 1996 Feb;173(2):330-9.

PMID:
8568293
43.
44.

Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.

D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM.

AIDS. 1995 Aug;9(8):867-74.

PMID:
7576320
45.

Sensitivities of radioimmunoprecipitation assay and PCR for detection of human T-lymphotropic type II infection.

Gallo D, Penning LM, Diggs JL, Hanson CV.

J Clin Microbiol. 1994 Oct;32(10):2464-7.

46.
47.

Measuring vaccine-induced HIV neutralization: report of a workshop.

Hanson CV.

AIDS Res Hum Retroviruses. 1994 Jun;10(6):645-8. No abstract available.

PMID:
8074928
48.

Photochemical inactivation of pathogenic bacteria in human platelet concentrates.

Lin L, Londe H, Janda JM, Hanson CV, Corash L.

Blood. 1994 May 1;83(9):2698-706.

49.

Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Sawyer LS, Wrin MT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, Hanson CV.

J Virol. 1994 Mar;68(3):1342-9.

50.

Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.

Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV.

J Acquir Immune Defic Syndr. 1994 Mar;7(3):211-9.

PMID:
8106963

Supplemental Content

Loading ...
Support Center